SecBot SecBot
8-K ·Filed Sep 10, 2026

IRON

Disc Medicine, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001193125-26-387351
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

This is a significant clinical catalyst that validates DISC-3405's mechanism and supports a path to pivotal trials. Traders should watch for the next data update (RESTORE-PV and sickle cell disease) and FDA feedback on selcodebart, both expected by year-end 2026. The stock is likely to re-rate higher on reduced pipeline risk.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$74.14
T+0 close · Sep 10, 2026 · via day close
Latest settled
−18.03%
T+20 · $60.77 · next T+60 in 17d
Vs SPY
−20.16%
α at T+20
Latest observation
+16.92%
T+45 · FF3 residual α
  1. T+0 · Sep 10 $74.14entry
  2. T+1 · 2mo ago −5.50%α −6.36% · $70.06
  3. T+5 · 2mo ago −6.69%α −6.19% · $69.18
  4. T+20 · 6w ago −18.03%α −20.16% · $60.77
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Disc Medicine announced positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at the SOHO conference. The drug demonstrated a significant reduction in phlebotomy events (from 4.0 to 0.6 over 26 weeks, p<0.0001), controlled hematocrit, and was well-tolerated. This is a strong clinical proof-of-concept for a novel mechanism in a large, underserved market (~150,000 US patients), de-risking the program and supporting advancement toward pivotal development.

Key Facts

  • DISC-3405 reduced mean total phlebotomy events from 4.0 to 0.6 over 26 weeks (p<0.0001) in Cohort A.
  • 61.5% of patients completing 26 weeks were entirely phlebotomy-free post-baseline.
  • 77.8% of patients completing the first maintenance period (weeks 12-32) remained phlebotomy-free.
  • Mean hematocrit was maintained stably below 45% through week 26.
  • DISC-3405 was generally well-tolerated with mild, self-limited injection site reactions.
  • The company plans to provide an update on RESTORE-PV and initial Phase 1b data in sickle cell disease by end of 2026.
  • Disc also expects to share FDA end-of-Phase 2 feedback and plans for pivotal development of selcodebart in MF by year-end.

Financial Impact

Positive clinical data de-risks a pipeline asset targeting a ~150,000-patient US market. No financial figures were disclosed in the filing.

Risk Factors

  • Data is from a small, open-label Phase 2 trial (n=13 completers in Cohort A) and may not replicate in larger, blinded studies.
  • Competition from existing PV therapies (phlebotomy, cytoreductives) and other novel agents in development.
  • Regulatory and commercial execution risk remains as the drug is still investigational.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-387351
Document: iron-ex99_1.htm0001193125-26-387351
Document: 0001193125-26-387351-index-headers.html0001193125-26-387351
Document: 0001193125-26-387351-index.html0001193125-26-387351
Document: 0001193125-26-387351.txt0001193125-26-387351

Track record

43 reports on IRON

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026